Holen Sie sich die Stockscreener-App
15.41
6.64%
1.0171
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum Therapeutics, Inc. Q1 2026 Financial Report: Earnings, Clinical Pipeline Progress, and Forward-Looking Statements 14 - Minichart
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones - BioSpace
Contineum (NASDAQ: CTNM) Q1 loss narrows, cash reaches $246.3M - Stock Titan
Chronic pain data and cash runway to 2029 for Contineum (NASDAQ: CTNM) - Stock Titan
Contineum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock - Investing.com
Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock By Investing.com - Investing.com South Africa
Contineum (NASDAQ: CTNM) CSO trims stake under 10b5-1 plan - Stock Titan
CTNM (NASDAQ: CTNM) affiliate reports multiple 10b5-1 sales by Daniel Lorrain - Stock Titan
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain - BioSpace
Contineum reports phase 1b trial results for chronic pain drug By Investing.com - Investing.com South Africa
Contineum Therapeutics : PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information - marketscreener.com
Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data - TipRanks
Contineum reports phase 1b trial results for chronic pain drug - Investing.com
[ARS] Contineum Therapeutics, Inc. SEC Filing - Stock Titan
Contineum Therapeutics (NASDAQ: CTNM) details 2026 virtual annual meeting - Stock Titan
Positive PIPE-791 chronic pain Phase 1b results for Contineum (NASDAQ: CTNM) - Stock Titan
Contineum’s MS drug falls short in Phase II trial - MSN
Is Contineum (CTNM) stock holding key zones | Q4 2025: EPS Misses ViewsFast Rising Picks - Cổng thông tin điện tử tỉnh Lào Cai
Contineum (CTNM) Stock High Reward Trade (Softens) 2026-04-20Community Trade Ideas - Xã Thanh Hà
Therapeutics Inc Gains Momentum In The Biotech Healthcare Sector - Kalkine Media
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Live Share Price, Invest From India - INDmoney
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth - Yahoo Finance
Contineum (CTNM) Stock: Risk Assessment (Investors Pile In) 2026-04-18Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Millennium Group (CTNM) reports shared 1,658,349-share stake via Schedule 13G - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Stock Price Up 2.2%Here's What Happened - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Bank Watch: Can Contineum Therapeutics Inc stock outperform in a bear marketWeekly Trade Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Contineum Therapeutics CSO sells $56k in CTNM stock - Investing.com UK
Contineum Therapeutics CSO sells $56k in CTNM stock By Investing.com - Investing.com India
Pre-planned stock sale by Contineum (CTNM) chief scientific officer - Stock Titan
Daniel Lorrain sells via 10b5-1; CTNM (NASDAQ: CTNM) Form 144 notice - Stock Titan
Should I Hold Contineum (CTNM) Stock Now | Price at $13.38, Down 0.48%High Attention Stocks - Newser
CTNM Stock Analysis: Contineum Therapeutics Inc posts 4.9 percent gain at 13.7 in recent trading - Newser
CTNM Technical Analysis & Stock Price Forecast - Intellectia AI
Contineum (CTNM) Q2 R&D Jumps 78% - aol.com
MACD Signal: Can Contineum Therapeutics Inc stock outperform in a bear market2026 Volume & Low Volatility Stock Recommendations - baoquankhu1.vn
Guidance Update: Is Contineum Therapeutics Inc currently under institutional pressure2026 Opening Moves & Stepwise Trade Signal Guides - baoquankhu1.vn
Sentiment Review: Is Contineum Therapeutics Inc currently under institutional pressureWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth - simplywall.st
Retail Trends: What is the Moat Score of Contineum Therapeutics Inc2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% HigherStill a Buy? - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Contineum Therapeutics, Inc.Common stock (NQ: CTNM - The Chronicle-Journal
Revenue Check: Is FKWL still a buy after recent gainsStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference - Defense World
Contineum Therapeutics, Inc. $CTNM Shares Sold by Baker BROS. Advisors LP - MarketBeat
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):